Second Quarter Report

June 30, 2018

MANAGEMENT DISCUSSION & ANALYSIS

June 30, 2018

August 2, 2018

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This discussion and analysis should be read in conjunction with the unaudited interim consolidated financial statements of Oncolytics Biotech® Inc. as at and for the three and six months ended June 30, 2018 and 2017, and and should also be read in conjunction with the audited consolidated financial statements and Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") contained in our annual report for the year ended December 31, 2017. The financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS").

FORWARD-LOOKING STATEMENTS

The following discussion contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and under applicable Canadian provincial securities legislation. Forward-looking statements, including our belief as to the potential of REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus, as a cancer therapeutic and our expectations as to the success of our research and development, clinical and manufacturing programs in 2018 and beyond, future financial position, business strategy and plans for future operations, and statements that are not historical facts, involve known and unknown risks and uncertainties, which could cause our actual results to differ materially from those in the forward-looking statements.

Such risks and uncertainties include, among others, the need for and availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, our ability to successfully commercialize pelareorep, uncertainties related to the research, development and manufacturing of pelareorep, uncertainties related to competition, changes in technology, the regulatory process and general changes to the economic environment.

With respect to the forward-looking statements made within this MD&A, we have made numerous assumptions regarding among other things: our ability to obtain financing to fund our clinical development plan, our ability to receive regulatory approval to commence enrollment in the clinical studies which are part of our clinical development plan, our ability to maintain our supply of pelareorep and future expense levels being within our current expectations.

Investors should consult our quarterly and annual filings with the Canadian and US securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Forward-looking statements are based on assumptions, projections, estimates and expectations of management at the time such forward-looking statements are made, and such assumptions, projections, estimates and/or expectations could change or prove to be incorrect or inaccurate. Investors are cautioned against placing undue reliance on forward-looking statements. We do not undertake to update these forward-looking statements except as required by applicable law.

REOLYSIN Development Update For 2018

Oncolytics Biotech Inc. is a Development Stage Company

Since our inception in April of 1998, Oncolytics Biotech Inc. has been a development stage company. We have focused our research and development efforts on the development of REOLYSIN, also known as pelareorep, an intravenously delivered immuno-oncolytic (I-O) virus with the potential to treat a variety of cancers. We have not been profitable since our inception and expect to continue to incur substantial losses as we continue research and development efforts. We do not expect to generate significant revenues until, and unless, pelareorep becomes commercially viable.

Our goal each year is to advance pelareorep through the various steps and stages of development required for potential pharmaceutical products. In order to achieve this goal, we believe that we have to actively manage the development of our clinical trial program, our pre-clinical and collaborative programs, our manufacturing process and pelareorep supply, and our intellectual property.

Clinical Trial Program

Our clinical development plan objectives are twofold. First, we are seeking to obtain regulatory approval for pelareorep based on the compelling metastatic breast cancer survival data that was presented at the 2017 American Association for Cancer Research (AACR) Annual Meeting, in Washington, D.C. Second, we are looking to expand pelareorep into commercially valuable new treatment areas that include immuno-therapy along with immuno-modulatory (IMiD) and other targeted agents in collaboration with pharmaceutical partners. Our clinical development program focuses on the three components of pelareorep's mechanism of action (MOA) and includes the following:

Chemotherapy combinations
Chemotherapy combinations focus on the investigation of chemotherapy combination clinical trials investigating the use of different chemotherapy agents in various cancer indications.

Targeted/IMiD combinations
Targeted/IMiD combinations focus on the potential of pelareorep to stimulate a patient's innate immunity and the potential for an infection to cause a cascade of chemokines/cytokines activating natural killer (NK) cells to attack cancer cells.

Immunotherapy combinations
Immunotherapy combinations focus on the potential for pelareorep to cause a specific adaptive immune response triggered by tumor- and viral-associated antigens displayed by antigen-presenting cells (APCs), infected tumor cells and/or dendritic cells to T cells.

Second Quarter 2018 Developments

Chemotherapy Combinations

Metastatic Breast Cancer
In 2017, we reported a statistically significant increase of 7 months (10.4 months to 17.4 months) in median overall survival from an open-label, randomized phase 2 metastatic breast cancer (mBC) study of intravenously-administered pelareorep given in combination with the chemotherapy agent paclitaxel. Pelareorep was awarded fast track designation by the United States Food and Drug Administration (FDA) for the treatment of mBC. We announced a productive End-of-Phase 2 meeting with the FDA for pelareorep in combination with paclitaxel, for the treatment of hormone receptor positive, HER2 receptor negative (HR+/HER2-) metastatic breast cancer (mBC) patients. The purpose of the meeting was to discuss the preclinical and clinical programs, including the design of the phase 3 registration study to support a future Biologics License Application (BLA) submission in the U.S. We also received a supportive Final Advice Letter from the European Medicines Agency (EMA) suggesting that a phase 3 study may be acceptable to form the basis of a Marketing Authorization Application (MAA) in Europe for the proposed use of pelareorep in combination with paclitaxel for the treatment of HR+/HER2- mBC. As a result of our statistically significant phase 2 data supported by a fast track designation, productive End-of-Phase 2 meeting with the FDA and supportive Final Advice Letter from the EMA, our objective is to advance pelareorep in combination with paclitaxel, into a phase 3 registration study for the treatment of HR+/HER2- mBC.

In May 2018, we reached agreement with the FDA under a Special Protocol Assessment for the protocol design, clinical endpoints and statistical analysis approach for our phase 3 clinical study evaluating pelareorep for the treatment of metastatic breast cancer.

Targeted/IMiD combinations

The initial activity supporting the innate immunity component of REOLYSIN's MOA, is in collaboration with Celgene Corporation (Celgene) and Myeloma UK, a cancer charity. MUK *eleven* was launched in March of 2017: a first of its kind immuno-therapy trial that aims to modulate the immune system to target myeloma. The Phase 1b trial will study REOLYSIN in combination with Celgene's Imnovid® (pomalidomide) or Revlimid® (lenalidomide) as a rescue treatment in relapsing myeloma patients. The dose escalation trial will look at the safety and tolerability of these combinations, and will investigate whether the addition of REOLYSIN extends disease control in this patient group.

The trial, which commenced enrollment in September 2017 and continued to enroll through the second quarter of 2018, will recruit approximately 44 patients across up to six Myeloma UK Clinical Trial Network centres in the UK. MUK *eleven* is part of the Myeloma UK Clinical Trial Network, a portfolio of early-stage trials coordinated by the Clinical Trials Research Unit at the University of Leeds, which aims to test and speed up access to promising new treatments for patients. Oncolytics and Celgene

UK & Ireland are providing their respective products for MUK *eleven*: Oncolytics is providing REOLYSIN and Celgene UK & Ireland is providing Imnovid® and Revlimid®.

Immunotherapy combinations

In support of the adaptive immunity component of the MOA, we expanded out immunotherapy combinations to include two additional research collaborations. In May 2018, we announced an investigator sponsored study supported by Merck Inc., Northwestern University and Oncolytics. This study is an extension of the REO 024 study that will investigate pelareorep in combination with Merck's anti-PD1 checkpoint inhibitor Keytruda®, to treat second line pancreatic cancer patients. The study will plan to enroll approximately 40 patients with advanced pancreatic cancer and will be conducted at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

As well, during the second quarter of 2018, we announced a collaboration with the Keck School of Medicine of University of Southern California (USC) using pelareorep in combination with Keytruda®, Velcade® and dexamethasone, to treat multiple myeloma. This study is an extension of the current REO 019 study evaluating pelareorep in combination with Velcade and dexamethasone to treat multiple myeloma and will be conducted at the USC Norris Comprehensive Cancer Center. It will add Keytruda which is being provided by Merck.

Pre-clinical/Research collaborations

During the second quarter of 2018, the following presentations were made:

Title	Presenter	Location	Description/Conclusion
Potentiating effect of reovirus in anti-PD1 therapy in colorectal cancer	Sanjay Goel, MD, Associate Professor of Medicine, Montefiore Medical Center	American Association for Cancer Research (AACR) Annual Meeting 2018, Chicago, Illinois	Data presented in the poster demonstrated: – pelareorep administration increased PD-L1 expression on MSS CRC cells; – possible evidence of a vaccine effect: immunologically competent mice were re-challenged with the original tumor and the tumor was unable to propagate; – combination therapy made statistically significant improvements in survival compared to controls in both BALB/c (median 42 vs. 16 days, p="0".003) and C57BL/6 (median 24 vs. 17 days, p="0".02) mice; and – pelareorep treated xenografted tumor tissue showed a higher infiltration of T lymphocytes as confirmed by CD8-positive and intensified granzyme staining.
Pelareorep promotes the expression of a chemokine signature that predicts response to immunotherapy	Grey Wilkinson, PhD, Translational Scientist, Oncolytics Biotech	American Association for Cancer Research (AACR) Annual Meeting 2018, Chicago, Illinois	Data presented in the poster demonstrated: – the expression of a chemokine signature that predicts response to immunotherapy; – global changes in gene expression are unique and different for each cell line following pelareorep infection and changes in gene expression occur before significant cell lysis; – pelareorep differentially promotes the expression of innate and adaptive immunity related genes in HCC, CRC, NSCLC cell lines; and – pelareorep promotes the expression of gene signatures that predict response to immuno-therapies in HCC cells.

B and T lymphocyte attenuator (BTLA) and PD-L1 significantly upregulated in reovirus treated TRAMP-C2 tumours	Dr. Guy Simpson, Department of Clinical and Experimental Medicine, University of Surrey	11th International Oncolytics Virus Conference (IOVC), Oxford, UK	Data presented in the poster demonstrated: – treatment of subcutaneous TRAMP-C2 prostate tumors with a combination of pelareorep and anti-PD-1 (Keytruda®) or anti-CD73 antibody significantly enhanced survival of mice compared to pelareorep or antibody therapy alone; – immune profiling of pelareorep treated and untreated tumors confirmed the ability of pelareorep to increase tumour immune cell infiltration; – pelareorep infection of tumours is needed before a therapeutic effect of anti-immune inhibitory/suppressive antibodies is seen; – pelareorep-initiated antitumor immunity protects against subsequent tumour challenge; and – after the study of negative regulators, only B and T lymphocyte attenuator (BTLA) and PD-L1 were significantly upregulated in the pelareorep treated TRAMP-C2 tumors compared to untreated tumour.
Pelareorep to promote the expression of a IFN-gamma-related gene signature that predicts response to checkpoint blockade therapy	Grey Wilkinson, PhD, Translational Scientist, Oncolytics Biotech	American Society of Clinical Oncoloty (ASCO) 2018 Annual Meeting, Chicago, Illinois	Highlights in the poster include: – Pelareorep promotes expression of gene signatures that are predictive of response to checkpoint inhibitors in select cell lines - HCC - hepatocellular carcinoma - HR+BC - hormone receptor positive breast cancer – Pronounced tumor inflammatory effects of pelareorep in HR+ BC cells may explain the prominent increase in overall survival in a previous phase 2 randomized clinical study in HR+ mBC patients treated with pelareorep and may render this large breast cancer population susceptible to conventional immunotherapy regimes – Results warrant further investigation of pelareorep in combination with checkpoint inhibitors

Manufacturing and Process Development

During the second quarter of 2018, we supplied our clinical development program with previously filled product from our existing supply of REOLYSIN, labeled for the applicable usage. As well, we continued our activities to source and develop commercial production capabilities to fill REOLYSIN into vials, the next step in the process validation master plan. Process validation is required to ensure that the resulting product meets required specifications and quality standards and will form part of the Company's submission to regulators, including the FDA, for product approval. We also commenced startup activities for drug product filling to support ongoing and upcoming clinical development projects.

Intellectual Property

At the end of the second quarter of 2018, we had been issued over 396 patents including 49 US and 21 Canadian patents as well as issuances in other jurisdictions. We have an extensive patent portfolio covering the oncolytic reovirus that we use in our clinical trial program including a composition of matter patent that expires in 2028. Our patent portfolio also includes methods for treating proliferative disorders using modified adenovirus, HSV, parapoxvirus and vaccinia virus.

Financing Activity

Share Consolidation

On May 22, 2018, we completed a consolidation of our common shares on the basis of 9.5 pre-consolidation common shares for each one post-consolidation common share (the "Share Consolidation"). Fractional interests were rounded down to the nearest whole number of common shares. Outstanding stock options, restricted share units and performance share units were similarly adjusted by the consolidation ratio. Outstanding warrants were adjusted such that, following the Share Consolidation, 9.5 pre-consolidation warrants entitle the holder to purchase one post-consolidation common share until June 1, 2022.

Listing on the Nasdaq Capital Market
On June 1, 2018, we announced that our common shares were approved for listing and commenced trading on the Nasdaq Capital Market.

Public offering
On June 5, 2018, we closed a public offering whereby we sold 1,532,278 common shares at a purchase price of US$5.83 per share for gross proceeds of US$8,933,181. We incurred share issue costs of $1,418,356.

"At-the-Market" equity distribution agreement
On February 25, 2016, we entered into an "at-the-market" equity distribution agreement with Canaccord Genuity Inc. acting as sole agent in Canada (our "Canadian ATM"). Under the terms of our Canadian ATM, we may, from time to time, sell shares of our common stock having an aggregate offering value of up to $4.6 million through Canaccord Genuity Inc. Sales of common shares, if any, pursuant to the Canadian ATM, will be made in transactions that are deemed to be "at-the-market distributions", through the facilities of the Toronto Stock Exchange or other "marketplace" (as defined in National Instrument 21-101 Marketplace Operation) in Canada. We will determine, at our sole discretion, the timing and number of shares to be sold under this ATM facility. During the six month period ending June 30, 2018, we sold 519,500 pre-consolidation common shares (approximately 54,684 post-consolidation common shares) for gross proceeds of $553,650. We incurred share issue costs of $33,335.

Options
During the second quarter of 2018, we received cash proceeds of $23,910 with respect to the exercise of 71,000 pre-consolidation options (approximately 7,473 post-consolidation options) by a former employee.

Warrants
During the second quarter of 2018, we received cash proceeds of $1,417 with respect to the exercise of 1,500 warrants.

Financial Impact

We estimated at the beginning of the second quarter of 2018 that our cash requirements to fund our operations for the year will be between $14 - $16 million depending on our ultimate clinical program. Our cash usage for the six month period ending June 30, 2018 was $4,019,494 for operating activities and $80,062 for the acquisition of property and equipment. Our net loss for the period was $8,882,113.

Cash Resources

We exited the second quarter of 2018 with cash and cash equivalents totaling $18,741,347 (see *"Liquidity and Capital Resources")*.

REOLYSIN Development for the Remainder of 2018

Our planned 2018 development activity for REOLYSIN focuses on our clinical development plan along with our manufacturing and intellectual property programs. For the remainder of 2018, our clinical objective is to incorporate our immuno-oncology combination strategy that includes checkpoint inhibitors, targeted therapies and other anti-cancer agents as we finalize our registration strategy and clinical protocol in preparation for a phase 3 clinical study in mBC. We expect to enter into additional clinical collaborations examining potential biomarkers and commence enrollment in our combination studies with Keytruda in second line pancreatic cancer and multiple myeloma. Our expectation is that these combination studies will assist us in refining our phase 3 protocol for mBC and may also support further development around the innate and adaptive immunity components of the mechanism of action.

Our 2018 manufacturing program includes preparation for continued production of 100-litre cGMP batches along with the related analytical testing and product filling, as well as labeling, packaging and shipping of REOLYSIN to our various clinical sites for ongoing and upcoming activities. These actions also contribute to progression through our process validation master plan and related conformity testing in 2018. Finally, our intellectual property program includes filings for additional patents along with monitoring activities required to protect our patent portfolio.

Second Quarter Results of Operations

(for the three months ended June 30, 2018 and 2017)

Net loss for the three month period ended June 30, 2018 was $4,211,439 compared to $4,349,142 for the three month period ended June 30, 2017.

Research and Development Expenses ("R&D")

	2018 $	2017 $
Clinical trial expenses	**813,555**	725,358
Manufacturing and related process development expenses	**441,066**	421,468
Intellectual property expenses	**183,712**	244,495
Research collaboration expenses	**37,681**	55,573
Other R&D expenses	**699,425**	1,488,106
Foreign exchange gain	**(159,573)**	(74,597)
Share based payments	**29,551**	58,270
Research and development expenses	**2,045,417**	2,918,673

Clinical Trial Expenses

	2018 $	2017 $
Clinical trial expenses	**813,555**	725,358

Our clinical trial expenses for the second quarter of 2018 were $813,555 compared to $725,358 for the second quarter of 2017. Our clinical trial program activities related primarily to the preparation and development of our breast cancer registration study. In the second quarter of 2018, these costs included phase 3 startup activities and activities related to obtaining the Special Protocol Assessment from the FDA, and in the second quarter of 2017 included costs to complete our supporting regulatory documents, regulatory filing fees and key opinion leader activities. During the second quarters of 2018 and 2017, our clinical trial activities also included patient enrollment in our checkpoint inhibitor pancreatic cancer study investigating pembrolizumab (KEYTRUDA®) in combination with REOLYSIN.

Manufacturing & Related Process Development Expenses ("M&P")

	2018 $	2017 $
Product manufacturing expenses	**384,609**	344,328
Process development expenses	**56,457**	77,140
Manufacturing and related process development expenses	**441,066**	421,468

Our M&P expenses for the second quarter of 2018 were $441,066 compared to $421,468 for the second quarter of 2017. During the second quarter of 2018, our product manufacturing costs included shipping and storage costs of our bulk and vialed product along with startup costs for a product fill required to support our clinical development plan. We were able to partially offset these costs by entering into a contract with a new storage depot with lower fees. During the second quarter of 2017, our product manufacturing costs mainly related to shipping and storage costs of our bulk and vialed product.

Our process development expenses for the second quarter of 2018 focused on analytic development and stability studies and in the second quarter of 2017 focused on stability studies.

Intellectual Property Expenses

	2018 $	2017 $
Intellectual property expenses	**183,712**	244,495

Our intellectual property expenses for the second quarter of 2018 were $183,712 compared to $244,495 for the second quarter of 2017. The change in intellectual property expenditures reflects the timing of filing costs associated with our patent base. At the end of the second quarter of 2018, we had been issued over 396 patents including 49 US and 21 Canadian patents, as well as issuances in other jurisdictions.

Research Collaboration Expenses

	2018 $	2017 $
Research collaboration expenses	**37,681**	55,573

Our research collaboration expenses were $37,681 for the second quarter of 2018 compared to $55,573 for the second quarter of 2017. Our research collaborations during the second quarters of 2018 and 2017 included biomarker studies and studies investigating the interaction of the immune system and pelareorep.

Other Research and Development Expenses

	2018 $	2017 $
R&D salaries and benefits	**640,710**	1,393,431
Other R&D expenses	**58,715**	94,675
Other research and development expenses	**699,425**	1,488,106

Our other research and development expenses were $699,425 for the second quarter of 2018 compared to $1,488,106 for the second quarter of 2017. The change in our R&D salaries and benefits was mainly due to severance payments to certain officers of the Company who were terminated during the second quarter of 2017. The change in our Other R&D expenses was due to a decrease in meeting attendance and related travel expenses.

Foreign Exchange Gain

	2018 $	2017 $
Foreign exchange gain	**(159,573)**	(74,597)

Our foreign exchange gain was $159,573 for the second quarter of 2018 compared to $74,597 for the second quarter of 2017. The change in foreign exchange gain was primarily due to the fluctuation in the U.S. dollar exchange rate on the translation of U.S. currency received from our June 2018 public offering and the settlement of our contract receivable.

Share Based Payments

	2018 $	2017 $
Share based payments	**29,551**	58,270

Non-cash share based payment expenses for the second quarter of 2018 were $29,551 compared to $58,270 for the second quarter of 2017. We incurred share based payment expenses associated with the granting of options and restricted share units to officers and employees associated with our research and development activities and the vesting of previously granted options and share awards. In the second quarter of 2018, we also recognized a recovery of share based payment expenses due to the departure of the Chief Medical Officer and the forfeiture of unvested share awards and options.

Operating Expenses

	2018 $	2017 $
Public company related expenses	**767,896**	760,560
Office expenses	**722,239**	560,857
Amortization of property and equipment	**21,126**	25,688
Share based payments	**127,541**	97,438
Operating expenses	**1,638,802**	1,444,543

Our operating expenses for the second quarter of 2018 were $1,638,802 compared to $1,444,543 for the second quarter of 2017. Public company related expenses include costs associated with investor relations, business development and financial advisory activities, legal and accounting fees, corporate insurance, director fees and transfer agent and other fees relating to our Canadian and U.S. stock listings. Our public company related expenses were $767,896 for the second quarter of 2018 compared to $760,560 for the second quarter of 2017. The change in our public company related expenses in the second quarter of 2018 was due to an increase in expenses related to the Nasdaq listing and an increase in travel expenses offset by a decrease in business development activities.

Office expenses include compensation costs (excluding share based payments), office rent and other office related costs. During the second quarter of 2018, our office expenses were $722,239 compared to $560,857 for the second quarter of 2017. The change was due to an investment in our business development department and an increase in office expenses related to the opening of our U.S. office.

Non-cash share based payment expenses in the second quarter of 2018 were $127,541 compared to $97,438 in the second quarter of 2017. We incurred share based payment expenses associated with the granting of options to officers and employees and the vesting of previously granted options and share awards.

Results of Operations

(for the six month period ending June 30, 2018 and 2017)

Net loss for the six month period ending June 30, 2018 was $8,882,113 compared to $7,866,861 for the six month period ending June 30, 2017.

Research and Development Expenses ("R&D")

	2018 $	2017 $
Clinical trial expenses	**1,846,300**	1,411,531
Manufacturing and related process development expenses	**858,769**	875,032
Intellectual property expenditures	**590,227**	496,085
Research collaboration expenses	**227,728**	142,952
Other R&D expenses	**1,411,276**	2,182,241
Foreign exchange gain	**(284,501)**	(47,200)
Share based payments	**330,509**	126,103
Research and development expenses	**4,980,308**	5,186,744

Clinical Trial Program

	2018 $	2017 $
Clinical trial expenses	**1,846,300**	1,411,531

Our clinical trial expenses were $1,846,300 for the six month period ending June 30, 2018 compared to $1,411,531 for the six month period ending June 30, 2017. Our clinical trial activities related primarily to the preparation and development of our breast cancer registration study. During the six month period ending June 30, 2018, these costs included phase 3 startup activities and activities related to obtaining the Special Protocol Assessment from the FDA, and in the six month period ending June 30, 2017 included costs to complete our supporting regulatory documents, regulatory filing fees and key opinion leader activities. During the six month periods ending June 30, 2018 and 2017, our clinical activities included patient enrollment in our checkpoint inhibitor pancreatic cancer study investigating pembrolizumab (KEYTRUDA®) in combination with REOLYSIN.

We still expect our clinical trial expenses to increase in 2018 compared to 2017. For the remainder of 2018, we expect to enter into additional clinical collaborations examining potential biomarkers and commence enrollment in our combination studies with Keytruda in second line pancreatic cancer and multiple myeloma as we finalize our registration strategy and clinical protocol in preparation for a phase 3 clinical study in mBC.

Manufacturing & Related Process Development ("M&P")

	2018 $	2017 $
Product manufacturing expenses	**637,312**	648,829
Process development expenses	**221,457**	226,203
Manufacturing and related process development expenses	**858,769**	875,032

Our M&P expenses for the six month period ending June 30, 2018 were $858,769 compared to $875,032 for the six month period ending June 30, 2017. During the six month periods ending June 30, 2018, our product manufacturing costs included shipping and storage costs of our bulk and vialed product along with startup costs for a product fill required to support our clinical development plan. We were able to largely offset these costs by entering into a contract with a new storage depot with lower fees. During the six month period ending June 30, 2017, our product manufacturing costs mainly related to shipping and storage costs of our bulk and vialed product.

Our process development expenses for the six month period ending June 30, 2018 were $221,457 compared to $226,203 for the six month period ending June 30, 2017. During the six month period ending June 30, 2018, our process development activities focused on analytic development and stability studies. During the six month period ending June 30, 2017, our activities focused on stability studies.

We still expect our M&P expenses for 2018 to increase compared to 2017. In 2018, we expect to fill, label and store sufficient product as we commence enrollment in our clinical development program and produce sufficient supply to support our registration efforts in breast cancer. We also expect to continue to perform stability testing and analytical development related to our process validation master plan and stability program.

Intellectual Property Expenses

	2018 $	2017 $
Intellectual property expenses	**590,227**	496,085

Our intellectual property expenses for the six month period ending June 30, 2018 were $590,227 compared to $496,085 for the six month period ending June 30, 2017. The change in intellectual property expenditures reflects the timing of filing costs associated with our patent base. At the end of the first half of 2018, we had been issued over 396 patents including 49 U.S. and 21 Canadian patents, as well as issuances in other jurisdictions.

We still expect that our intellectual property expenses will remain consistent in 2018 compared to 2017.

Research Collaborations

	2018 $	2017 $
Research collaborations	**227,728**	142,952

Our research collaboration expenses for the six month period ending June 30, 2018 were $227,728 compared to $142,952 for the six month period ending June 30, 2017. During the six month periods ending June 30, 2018 and 2017, our research collaborations included biomarker studies and studies investigating the interaction of the immune system and pelareorep.

We still expect that our research collaborations in 2018 will increase compared to 2017. We expect to complete our ongoing collaborative program carried over from 2017 and will continue to be selective in the types of new collaborations we enter into in 2018.

Other Research and Development Expenses

	2018 $	2017 $
R&D salaries and benefits	**1,300,870**	2,059,249
Other R&D expenses	**110,406**	122,992
Other research and development expenses	**1,411,276**	2,182,241

Our Other Research and Development expenses for the six month period ending June 30, 2018 were $1,411,276 compared to $2,182,241 for the six month period ending June 30, 2017. The change in our R&D salaries and benefits was mainly due to severance payments to certain officers of the Company who were terminated during the second quarter of 2017. The change in our Other R&D expenses was due to a decrease in meeting attendance and related travel expenses.

We now expect our Other R&D expenses to remain consistent in 2018 compared to 2017.

Foreign Exchange Gain

	2018 $	2017 $
Foreign exchange gain	**(284,501)**	(47,200)

Our foreign exchange gain for the six month period ending June 30, 2018 was $284,501 compared to $47,200 for the six month period ending June 30, 2017. The change in foreign exchange gain was primarily due to the fluctuation in the U.S. dollar exchange rate on the translation of U.S. currency received from our June 2018 public offering and the settlement of our contract receivable.

Share Based Payments

	2018 $	2017 $
Share based payments	**330,509**	126,103

During the six month period ending June 30, 2018, our non-cash share based payment expenses were $330,509 compared to $126,103 for the six month period ending June 30, 2017. We incurred share based payment expenses associated with the granting of options and share awards to officers and employees associated with our research and development activities and the vesting of previously granted options and share awards. In the second quarter of 2018, we also recognized a recovery of share based payment expenses due to the departure of the Chief Medical Officer and the forfeiture of unvested share awards and options. We granted 202,855 options and share awards in the six month period ending June 30, 2018 compared to 1,578 options and share awards in the six month period ending June 30, 2017.

Operating Expenses

	2018 $	2017 $
Public company related expenses	**1,565,730**	1,454,935
Office expenses	**1,428,940**	1,076,690
Amortization of property and equipment	**40,984**	49,724
Share based payments	**365,701**	163,494
Operating expenses	**3,401,355**	2,744,843

Our operating expenses for the six month period ending June 30, 2018 were $3,401,355 compared to $2,744,843 for the six month period ending June 30, 2017. Public company related expenses include costs associated with investor relations, business development and financial advisory activities, legal and accounting fees, corporate insurance, director fees and transfer agent and other fees relating to our U.S. and Canadian stock listings. During the six month period ending June 30, 2018, our public company related expenses were $1,565,730 compared to $1,454,935 for the six month period ending June 30, 2017. The change was due to an increase in expenses related to the Nasdaq listing, an increase in legal fees and costs related to the special meeting of shareholders held in February 2018 and an increase in travel expenses, partly offset by a decrease in business development activities.

Office expenses include compensation costs (excluding share based payments), office rent, and other office related costs. During the six month period ending June 30, 2018, we incurred office expenses of $1,428,940 compared to $1,076,690 during the six month period ending June 30, 2017. The change was due to an investment in our business development department and an increase in office expenses related to the opening of our U.S. office.

During the six month period ending June 30, 2018, our non-cash share based payment expenses were $365,701 compared to $163,494 for the six month period ending June 30, 2017. We incurred share based payment expenses associated with the granting of stock options to officers and employees and the vesting of previously granted options and share awards. We granted 119,903 options and share awards in the six month period ending June 30, 2018 compared to 28,684 options and share awards in the six month period ending June 30, 2017.

We still expect our operating expenses in 2018 to increase compared to 2017.

Commitments

As at June 30, 2018, we are committed to payments totaling approximately $6,063,389 for activities related to our clinical trial, manufacturing and collaboration programs which are expected to occur over the next two years. We are committed to rental payments (excluding our portion of operating costs and rental taxes) under the terms of our office leases totaling $1,183,174 for 2018 to 2021. All of these committed payments are considered to be part of our normal course of business.

Summary of Quarterly Results

	2018			2017			2016	
	June	Mar	Dec	Sept	June	Mar	Dec	Sept
Revenue	—	—	—	—	—	—	—	—
Net loss[2]	4,211	4,671	4,746	3,004	4,349	3,518	5,210	3,332
Basic and diluted loss per common share[2]	$ 0.27	$ 0.31	$ 0.32	$ 0.20	$ 0.32	$ 0.28	$ 0.41	$ 0.26
Total assets[3]	20,693	14,127	18,150	14,848	17,579	10,623	14,758	18,437
Total cash[1], [3]	18,741	7,745	11,836	14,034	16,676	10,102	14,123	17,702
Total long-term debt	—	—	—	—	—	—	—	—
Cash dividends declared[4]	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil

(1) Included in total cash are cash and cash equivalents plus short-term investments.

(2) The calculation of basic and diluted loss per common share for all periods has been adjusted retrospectively for the Share Consolidation. Included in net loss and loss per common share between June 2018 and July 2016 are quarterly share based payment expenses of $157,092, $539,118, $140,659, $148,447, $155,708, $133,889, $106,443 and $98,369, respectively.

(3) We issued 590,500 pre-consolidation common shares (approximately 62,157 post-consolidation common shares) for net cash proceeds of $0.5 million and 1,532,435 post-consolidation common shares for net cash proceeds of $10.2 million in 2018 (2017 - 20,547,500 pre-consolidation common shares (approximately 2,162,894 post-consolidation common shares) for net cash proceeds of $12.8 million).

(4) We have not declared or paid any dividends since incorporation.

Liquidity and Capital Resources

2018 Financing Activities

Share Consolidation

On May 22, 2018, we completed a consolidation of our common shares on the basis of 9.5 pre-consolidation common shares for each one post-consolidation common share (the "Share Consolidation"). Fractional interests were rounded down to the nearest whole number of common shares. Outstanding stock options, restricted share units and performance share units were similarly adjusted by the consolidation ratio. Outstanding warrants were adjusted such that, following the Share Consolidation, 9.5 pre-consolidation warrants entitle the holder to purchase one post-consolidation common share until June 1, 2022.

Listing on the Nasdaq Capital Market

On June 1, 2018, we announced that our common shares were approved for listing and commenced trading on the Nasdaq Capital Market.

Public offering

On June 5, 2018, we closed a public offering whereby we sold 1,532,278 post-consolidation common shares at a purchase price of US$5.83 per share for gross proceeds of US$8,933,181. We incurred share issue costs of $1,418,356.

Canadian "At-the-Market" equity distribution agreement

During the six month period ending June 30, 2018, we sold 519,500 pre-consolidation common shares (approximately 54,684 post-consolidation common shares) for net proceeds of $520,315.

Options

During the second quarter of 2018, we received cash proceeds of $23,910 with respect to the exercise of 71,000 pre-consolidation options (approximately 7,473 post-consolidation options) by a former employee.

Warrants

During the second quarter of 2018, we received cash proceeds of $1,417 with respect to the exercise of 1,500 warrants.

2017 Financing Activities

Canadian "At-the-Market" equity distribution agreement

During the six month period ending June 30, 2017, we sold 842,000 pre-consolidation common shares (approximately 88,631 post-consolidation common shares) for gross proceeds of $668,648. We incurred share issue costs of $109,121.

Public offering
On June 1, 2017, pursuant to an underwritten public offering, 16,445,000 units were sold at a purchase price of $0.70 per unit for gross proceeds of $11,511,500. Each unit included one pre-consolidation common share (0.106 post-consolidation common share) and one common share purchase warrant. Following the Share Consolidation, 9.5 common share purchase warrants entitle the holder to purchase one common share in the capital of the Company until June 1, 2022, at an exercise price of approximately $9.025. The post-consolidation common share purchase warrants will be subject to acceleration if the volume weighted average price of the Company's common shares equals or exceeds $23.75 for 15 consecutive trading dates. We incurred share issue costs of $1,145,402.

Options
During the second quarter of 2017, we received cash proceeds of $295,350 with respect to the exercise of 686,500 pre-consolidation options (approximately 72,263 post-consolidation options) by former employees.

Liquidity

As at June 30, 2018, we had cash and cash equivalents and working capital positions as follows:

	June 30, 2018 $	**December 31, 2017 $**
Cash and cash equivalents	**18,741,347**	11,836,119
Working capital position	**16,396,435**	12,587,340

We do not have any debt other than trade accounts payable and we have potential contingent obligations relating to the completion of our research and development of REOLYSIN.

In managing our capital, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the costs associated with these activities. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year's activity. Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.

Historically, funding for our plan is primarily managed through the issuance of additional common shares and common share purchase warrants that upon exercise are converted to common shares. Management regularly monitors the capital markets attempting to balance the timing of issuing additional equity with our progress through our clinical trial program, general market conditions, and the availability of capital. There are no assurances that funds will be made available to us when required.

On May 4, 2018, we renewed our short form base shelf prospectus (the "Base Shelf") that qualifies for distribution of up to 150,000,000 of common shares, subscription receipts, warrants, or units (the "Securities") in either Canada, the US or both. Under a Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents or other intermediaries and also may sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.

Renewing our Base Shelf provides us with additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time period required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in our company. Funds received as a result of using our Base Shelf would be used in line with our Board approved budget and multi-year plan. Our renewed Base Shelf will be effective until May 25, 2020.

We anticipate that the expected cash usage from our operations in 2018 will be between $14 - $16 million. We continue to manage our research and development plan with the objective of ensuring optimal use of our existing resources. Additional activities continue to be subject to adequate resources and we believe we will have sufficient cash resources to fund our presently planned operations to the end of 2018. We also anticipate entering into new financing arrangements to fund our operations. Factors that will affect our anticipated cash usage in 2018, and for which additional funding might be required include, but are not limited to, expansion of our clinical trial program, the timing of patient enrollment in our approved clinical trials, the actual costs incurred to support each clinical trial, the number of treatments each patient will receive, the timing of R&D activity with our clinical trial

research collaborations, the number, timing and costs of manufacturing runs required to conclude the validation process and supply product to our clinical trial program, and the level of collaborative activity undertaken.

We are not subject to externally imposed capital requirements and there have been no changes in how we define or manage our capital in 2018.

Financial Instruments and Other Instruments

Our financial instruments consist of cash and cash equivalents, other receivables and accounts payable. As at June 30, 2018, there are no significant differences between the carrying values of these amounts and their estimated market values. These financial instruments expose us to the following risks:

Credit risk

Credit risk is the risk of financial loss if a counter-party to a financial instrument fails to meet its contractual obligations. We are exposed to credit risk on our cash and cash equivalents and contract receivable in the event of non-performance by counterparties, but we do not anticipate such non-performance. Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents and contract receivable.

We mitigate our exposure to credit risk by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada. For our foreign domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts and these accounts are used solely for the purpose of settling accounts payable or payroll.

Interest rate risk

Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in market interest rates. We are exposed to interest rate risk through our cash and cash equivalents and our portfolio of short-term investments. We mitigate this risk through our investment policy that only allows investment of excess cash resources in investment grade vehicles while matching maturities with our operational requirements.

Fluctuations in market rates of interest do not have a significant impact on our results of operations due to the short term to maturity of the investments held.

Currency risk

Currency risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. In the normal course of our operations, we are exposed to currency risk from the purchase of goods and services primarily in the U.S., the U.K. and the European Union. In addition, we are exposed to currency risk to the extent cash is held in foreign currencies from either the purchase of foreign currencies or when we receive foreign currency proceeds from operating and financing activities. As well, we are exposed to currency risk related to our regional licensing agreement. The impact of a $0.01 increase in the value of the U.S. dollar against the Canadian dollar would have decreased our net loss in 2018 by approximately $78,308. The impact of a $0.10 increase in the value of the British pound against the Canadian dollar would have increased our net loss in 2018 by approximately $15,848. The impact of a $0.10 increase in the value of the Euro against the Canadian dollar would have increased our net loss in 2018 by approximately $4,658.

We mitigate our foreign exchange risk by maintaining sufficient foreign currencies, through the purchase of foreign currencies or receiving foreign currencies from financing activities, to settle our foreign accounts payable.

Balances in foreign currencies at June 30, 2018 are as follows:

	US dollars $	British pounds £	Euro €
Cash and cash equivalents	12,698,664	29,212	23,347
Accounts payable	(916,806)	(27,060)	—
	11,781,858	2,152	23,347

Liquidity risk

Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities. We manage liquidity risk through the management of our capital structure as outlined in Note 10 of our interim consolidated financial statements. Accounts payable are all due within the current operating period.

Other MD&A Requirements

We have 16,531,956 common shares outstanding at August 2, 2018. If all of our options, restricted share units and performance share units (1,153,080) and common share purchase warrants (1,730,894) were exercised or were to vest, we would have 19,415,930 common shares outstanding.

Our 2017 annual report on Form 20-F is available on www.sedar.com.

Disclosure Controls and Procedures

There were no changes in our internal controls over financial reporting during the quarter ended June 30, 2018 that materially affected or are reasonably likely to materially affect, our internal controls over financial reporting.

Interim Consolidated Financial Statements
(unaudited)

Oncolytics Biotech® Inc.
June 30, 2018 and 2017

ONCOLYTICS BIOTECH INC.
INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
(unaudited)

As at	Notes	June 30, 2018 $	December 31, 2017 $
Assets			
Current assets			
Cash and cash equivalents	*4*	**18,741,347**	11,836,119
Contract receivable	*8*	**—**	4,767,100
Other receivables		**89,714**	37,726
Prepaid expenses		**1,489,212**	1,176,063
Total current assets		**20,320,273**	17,817,008
Non-current assets			
Property and equipment		**373,213**	333,441
Total non-current assets		**373,213**	333,441
Total assets		**20,693,486**	18,150,449
Liabilities And Shareholders' Equity			
Current Liabilities			
Accounts payable and accrued liabilities		**2,996,438**	3,684,023
Contract liability	*8*	**927,400**	1,545,645
Total current liabilities		**3,923,838**	5,229,668
Non-current liabilities			
Contract liability	*8*	**5,802,887**	4,636,935
Total non-current liabilities		**5,802,887**	4,636,935
Total liabilities		**9,726,725**	9,866,603
Commitments and contingencies	*9*		
Shareholders' equity			
Share capital Authorized: unlimited Issued: June 30, 2018 – 16,521,430 December 31, 2017 – 141,805,722 pre-consolidation December 31, 2017 – 14,926,918 post-consolidation	*5*	**282,458,995**	271,710,138
Warrants	*5*	**3,617,570**	3,617,900
Contributed surplus	*6*	**27,710,089**	27,028,238
Accumulated other comprehensive income		**508,380**	373,730
Accumulated deficit		**(303,328,273)**	(294,446,160)
Total shareholders' equity		**10,966,761**	8,283,846
Total liabilities and equity		**20,693,486**	18,150,449

See accompanying notes

ONCOLYTICS BIOTECH INC.
INTERIM CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS
(unaudited)

	Notes	Three Month Period Ending June 30, 2018 $	Three Month Period Ending June 30, 2017 $	Six Month Period Ending June 30, 2018 $	Six Month Period Ending June 30, 2017 $
Expenses					
Research and development	*6, 13, 14*	**2,045,417**	2,918,673	**4,980,308**	5,186,744
Operating	*6, 13, 14*	**1,638,802**	1,444,543	**3,401,355**	2,744,843
Loss before the following		**(3,684,219)**	(4,363,216)	**(8,381,663)**	(7,931,587)
Interest		**20,538**	14,163	**47,428**	64,878
Loss before income taxes		**(3,663,681)**	(4,349,053)	**(8,334,235)**	(7,866,709)
Income tax expense		**(547,758)**	(89)	**(547,878)**	(152)
Net loss		**(4,211,439)**	(4,349,142)	**(8,882,113)**	(7,866,861)
Other comprehensive income (loss) items that may be reclassified to net loss					
Translation adjustment		**64,029**	(44,740)	**134,650**	(65,488)
Net comprehensive loss		**(4,147,410)**	(4,393,882)	**(8,747,463)**	(7,932,349)
Basic and diluted loss per common share	*7*	**(0.27)**	(0.32)	**(0.58)**	(0.60)
Weighted average number of shares (basic and diluted)	*7*	**15,406,944**	13,405,220	**15,191,457**	13,086,393

See accompanying notes

ONCOLYTICS BIOTECH INC.
INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
(unaudited)

	Notes	Share Capital $	Warrants $	Contributed Surplus $	Accumulated Other Comprehensive Income $	Accumulated Deficit $	Total $
As at December 31, 2016		262,321,825	—	26,643,044	554,060	(278,829,309)	10,689,620
Net loss and other comprehensive loss		—	—	—	(65,488)	(7,866,861)	(7,932,349)
Issued pursuant to "At the Market" agreement	*5*	668,648	—	—	—	—	668,648
Issued pursuant to public offering	*5*	7,893,600	3,617,900	—	—	—	11,511,500
Issued pursuant to stock option plan	*6*	461,823	—	(166,473)	—	—	295,350
Share based compensation	*6*	—	—	289,597	—	—	289,597
Share issue costs	*5*	(1,254,523)	—	—	—	—	(1,254,523)
As at June 30, 2017		270,091,373	3,617,900	26,766,168	488,572	(286,696,170)	14,267,843
As at December 31, 2017		271,710,138	3,617,900	27,028,238	373,730	(294,446,160)	8,283,846
Net loss and other comprehensive income		—	—	—	134,650	(8,882,113)	(8,747,463)
Issued pursuant to "At the Market" Agreement	*5*	553,650	—	—	—	—	553,650
Issued pursuant to public offering	*5*	11,606,882	—	—	—	—	11,606,882
Issued pursuant to stock option plan	*6*	38,269	—	(14,359)	—	—	23,910
Issued pursuant to warrant agreement	*5*	1,747	(330)	—	—	—	1,417
Share based compensation	*6*	—	—	696,210	—	—	696,210
Share issue costs	*5*	(1,451,691)	—	—	—	—	(1,451,691)
As at June 30, 2018		**282,458,995**	**3,617,570**	**27,710,089**	**508,380**	**(303,328,273)**	**10,966,761**

See accompanying notes

ONCOLYTICS BIOTECH INC.
INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)

	Notes	Three Month Period Ending June 30, 2018 $	Three Month Period Ending June 30, 2017 $	Six Month Period Ending June 30, 2018 $	Six Month Period Ending June 30, 2017 $
Operating Activities					
Net loss for the period		**(4,211,439)**	(4,349,142)	**(8,882,113)**	(7,866,861)
Amortization - property and equipment	*13*	**21,126**	25,688	**40,984**	49,724
Share based compensation	*6, 13, 14*	**157,092**	155,708	**696,210**	289,597
Unrealized foreign exchange gain		**(97,832)**	(164,676)	**(102,345)**	(112,644)
Net change in non-cash working capital	*12*	**4,720,317**	(216,906)	**4,227,770**	(854,552)
Cash provided by (used in) operating activities		**589,264**	(4,549,328)	**(4,019,494)**	(8,494,736)
Investing Activities					
Acquisition of property and equipment		**(37,443)**	(80,050)	**(80,062)**	(85,886)
Redemption of short-term investments		**—**	—	**—**	2,088,800
Cash (used in) provided by investing activities		**(37,443)**	(80,050)	**(80,062)**	2,002,914
Financing Activities					
Proceeds from "At the Market" equity distribution agreement	*5*	**—**	570,027	**520,315**	559,527
Proceeds from public offering	*5*	**10,188,526**	10,366,098	**10,188,526**	10,366,098
Proceeds from exercise of options	*6*	**23,910**	295,350	**23,910**	295,350
Proceeds from exercise of warrants	*5*	**1,417**	—	**1,417**	—
Cash provided by financing activities		**10,213,853**	11,231,475	**10,734,168**	11,220,975
Increase in cash		**10,765,674**	6,602,097	**6,634,612**	4,729,153
Cash and cash equivalents, beginning of period		**7,745,255**	10,102,393	**11,836,119**	12,034,282
Impact of foreign exchange on cash and cash equivalents		**230,418**	(28,192)	**270,616**	(87,137)
Cash and cash equivalents, end of period		**18,741,347**	16,676,298	**18,741,347**	16,676,298

See accompanying notes

Note 1: Incorporation and Nature of Operations

Oncolytics Biotech Inc. was incorporated on April 2, 1998 under the Business Corporations Act (Alberta) as 779738 Alberta Ltd. On April 8, 1998, we changed our name to Oncolytics Biotech Inc.

Our interim consolidated financial statements for the period ended June 30, 2018, were authorized for issue in accordance with a resolution of the Board of Directors (the "Board") on August 2, 2018. We are a limited company incorporated and domiciled in Canada. Our shares are publicly traded and our registered office is located at 210, 1167 Kensington Crescent NW, Calgary, Alberta, Canada.

We are a development stage biopharmaceutical company that focuses on the discovery and development of pharmaceutical products for the treatment of cancers that have not been successfully treated with conventional therapeutics. Our lead product, REOLYSIN®, is a potential immuno-oncology viral-agent that may be a novel treatment for certain types of cancer and may be an alternative to existing cytotoxic or cytostatic therapies. Our clinical development program for REOLYSIN emphasizes three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator (IMiD) combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses.

Note 2: Basis of Financial Statement Presentation

Our interim consolidated financial statements include our financial statements and the financial statements of our subsidiaries as at June 30, 2018 and are presented in Canadian dollars, our functional currency.

Our accounts are prepared in accordance with International Financial Reporting Standards ("IFRS") issued by the International Accounting Standards Board ("IASB"). The accounts are prepared on the historical cost basis, except for certain assets and liabilities which are measured at fair value as explained in the notes to these financial statements.

These interim consolidated financial statements have been prepared in compliance with International Accounting Standard 34 *Interim Financial Reporting.* The notes presented in these interim consolidated financial statements include only significant events and transactions occurring since our last fiscal year end and are not fully inclusive of all matters required to be disclosed in our annual audited consolidated financial statements. Accordingly, these interim consolidated financial statements should be read in conjunction with our most recent annual audited consolidated financial statements, for the year ended December 31, 2017. We have consistently applied the same accounting policies for all periods presented in these interim consolidated financial statements as those used in our audited consolidated financial statements for the year ended December 31, 2017, except for the adoption of new standards effective as of January 1, 2018.

Note 3: Significant Accounting Policies

IFRS 9 - *Financial Instruments*

IFRS 9 *Financial Instruments ("IFRS 9")* replaces IAS 39 *Financial Instruments: Recognition and Measurement* for annual periods beginning on or after January 1, 2018. IFRS 9 includes guidance on the classification and measurement of financial assets and financial liabilities and impairment of financial assets.

We have applied IFRS 9 retrospectively, with the initial application date of January 1, 2018. There were no changes to the measurement of our financial assets and liabilities or adjustments to comparative information as a result of the adoption of IFRS 9.

(a) Classification and measurement

Financial assets
Financial assets are initially measured at fair value. In the case of a financial asset not at fair value through profit or loss, the financial asset is initially measured at fair value plus or minus transaction costs.

Under IFRS 9, financial assets are subsequently measured at amortised cost, fair value through profit or loss (FVPL), or fair value through other comprehensive income (FVOCI). The classification is based on two criteria: the Company's business model for managing the assets; and whether the financial asset's contractual cash flows represent 'solely payments of principal and interest' on the principal amount outstanding (the 'SPPI criterion').

Our financial assets include cash and cash equivalents and other receivables. The classification and measurement of these financial assets are at amortized cost, as these assets are held within our business model with the objective to hold the financial assets in order to collect contractual cash flows that meet the SPPI criterion. Under IAS 39, our financial assets were classified as follows: cash and cash equivalents - held for trading and other receivables - loans and receivables. The accounting for our financial assets remained the same as it was under IAS 39.

Financial liabilities
Financial liabilities are initially measured at fair value and are subsequently measured at amortised cost. The accounting for our financial liabilities remained the same as it was under IAS 39.

(b) Impairment

Under IFRS 9, accounting for impairment losses for financial assets uses a forward-looking expected credit loss (ECL) approach.

IFRS 9 requires that we record a loss allowance for ECLs on all financial assets not held at FVPL. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive. The shortfall is then discounted at an approximation to the asset's original effective interest rate.

We have applied the simplified approach permitted by IFRS 9 and calculated ECLs based on lifetime expected credit losses. We have established a provision matrix that is based on historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic environment.

There were no adjustments in impairment allowances of our financial assets as a result of the adoption of the ECL requirements of IFRS 9.

Note 4: Cash Equivalents

Cash Equivalents
Cash equivalents consist of interest bearing deposits with our bank totaling $12,814,805 (December 31, 2017 – $9,204,919). The current annual interest rate earned on these deposits is 1.46% (December 31, 2017 – 1.38%).

Note 5: Share Capital

Authorized:
Unlimited number of no par value common shares

Share Consolidation:
On May 22, 2018, we completed the consolidation of our common shares on the basis of 9.5 pre-consolidation common shares for each one post-consolidation common share (the "Share Consolidation"). Fractional interests were rounded down to the nearest whole number of common shares. Outstanding stock options, restricted share units and performance share units were similarly adjusted by the consolidation ratio. Outstanding warrants were adjusted such that, following the Share Consolidation, 9.5 2017 warrants will entitle the holder to purchase one whole common share until June 1, 2022.

Issued:	Shares		Warrants	
	Number	Amount $	Number	Amount $
Balance, December 31, 2016	121,258,222	262,321,825	—	—
Issued pursuant to stock option plan	801,000	536,949	—	—
Issued pursuant to "At the Market" equity distribution agreement[(a)]	3,301,500	2,348,821	—	—
Issued pursuant to public offering[(b)]	16,445,000	7,893,600	16,445,000	3,617,900
Share issue costs	—	(1,391,057)	—	—
Balance, December 31, 2017	141,805,722	271,710,138	16,445,000	3,617,900
Issued pursuant to "At the Market" equity distribution agreement[(a)]	519,500	553,650	—	—
Share issue costs	—	(33,335)	—	—
Balance, March 31, 2018	142,325,222	272,230,453	16,445,000	3,617,900
Issued pursuant to stock option plan	71,000	38,269	—	—
Balance, May 22, 2018 - pre-consolidation	142,396,222	272,268,722	16,445,000	3,617,900
Balance, May 22, 2018 - post-consolidation	14,988,995	272,268,722	16,445,000	3,617,900
Issued pursuant to public offering[(c)]	1,532,278	11,606,882		
Issued pursuant to warrant agreement	157	1,747	(1,500)	(330)
Share issue costs	—	(1,418,356)		
Balance, June 30, 2018	**16,521,430**	**282,458,995**	**16,443,500**	**3,617,570**

(a) On February 25, 2016, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. acting as our sole agent with an aggregate offering value of up to $4.6 million which allows us to sell our common shares through the facilities of the Toronto Stock Exchange or other "marketplace" (as defined in National Instrument 21-101 Marketplace Operation) in Canada (our "Canadian ATM"). Subject to the terms of our Canadian ATM, we are able to determine, at our sole discretion, the timing and number of shares to be sold under this ATM facility. During the period ending June 30, 2018, we sold 519,500 pre-consolidation shares (approximately 54,684 post-consolidation shares) (2017 - 842,000 pre-consolidation shares (approximately 88,631 post-consolidation shares)) for gross proceeds of $553,650 (2017 - $668,648). We incurred share issue costs of $33,335 (2017 - $109,121).

(b) On June 1, 2017, pursuant to an underwritten public offering, 16,445,000 units were sold at a purchase price of $0.70 per unit for gross proceeds of $11,511,500. Each unit included one pre-consolidation common share with an ascribed value of $0.48 (0.106 post-consolidation common share with an ascribed value of $4.56) and one pre-consolidation common share purchase warrant with an ascribed value of $0.22 (one post-consolidation common share purchase warrant with an ascribed value of $2.09). Each pre-consolidation common share purchase warrant entitled the the holder to purchase one pre-consolidation common share at an exercise price of $0.95. Following the Share Consolidation, 9.5 pre-consolidation common share purchase warrants entitles the holder to purchase one post-consolidation common share in the capital of the Company until June 1, 2022,

at an exercise price of approximately $9.025. The post-consolidation common share purchase warrants will be subject to acceleration if the volume weighted average price of the Company's common shares equals or exceeds $23.75 for 15 consecutive trading dates. The ascribed value was determined using the relative fair value method. The ascribed value of the common share purchase warrants was determined using the Black Scholes option pricing model. We incurred share issue costs of $1,145,402.

(c) On June 5, 2018, pursuant to an underwritten public offering, 1,532,278 common shares were sold at a purchase price of US $5.83 per share for gross proceeds of US$8,933,181. We incurred share issue costs of $1,418,356.

Warrants

The following table summarizes our outstanding warrants at June 30, 2018:

Exercise Price	Outstanding, Beginning of the Period	Granted During the Period	Exercised During the Period	Outstanding, End of the Period	Weighted Average Remaining Contractual Life (years)
$ 9.025	16,445,000	—	(1,500)	16,443,500	3.92

Note 6: Share Based Payments

On May 22, 2018, we completed our Share Consolidation (see Note 5), as a result, all stock option and share award disclosures have been retrospectively adjusted to reflect the Share Consolidation.

Stock Option Plan

We have issued stock options to acquire common stock through our stock option plan of which the following are outstanding at June 30:

	2018		2017	
	Stock Options	Weighted Average Exercise Price $	Stock Options	Weighted Average Exercise Price $
Outstanding, beginning of the period	**647,156**	**13.20**	912,995	18.71
Granted during the period	**313,867**	**7.38**	14,735	2.82
Forfeited during the period	**(39,680)**	**7.33**	(73,887)	30.94
Expired during the period	—	—	(1,882)	21.38
Exercised during the period	**(7,473)**	**3.20**	(72,250)	4.09
Outstanding, end of the period	**913,870**	**11.54**	779,711	17.10
Options exercisable, end of the period	**666,693**	**13.35**	606,905	21.02

The following table summarizes information about the stock options outstanding and exercisable at June 30, 2018:

Range of Exercise Prices	Number Outstanding	Weighted Average Remaining Contractual Life (years)	Weighted Average Exercise Price $	Number Exercisable	Weighted Average Exercise Price $
$2.47 - $3.99	342,454	7.5	3.36	304,436	3.29
$4.84 - $7.60	345,225	4.3	7.18	136,066	7.17
$13.77 - $19.00	103,956	4.7	16.87	103,956	16.87
$20.23 - $36.96	56,722	3.0	32.47	56,722	32.47
$38.09 - $63.84	65,513	3.1	50.74	65,513	50.74
	913,870	5.4	11.54	666,693	13.35

Non-exercisable options vest either annually over periods ranging from one to three years.

The estimated fair value of stock options issued during the period was determined using the Black Scholes Option Pricing Model using the following weighted average assumptions and fair value of options:

	2018	2017
Risk-free interest rate	**1.88%**	0.90%
Expected hold period to exercise	**3.0 years**	3.0 years
Volatility in the price of the Company's shares	**84.11%**	88.71%
Rate of forfeiture	**3.67%**	3.67%
Dividend yield	**Nil**	Nil
Weighted average fair value of options	**$4.04**	$2.05

We use historical data to estimate the expected dividend yield and expected volatility of our stock in determining the fair value of the stock options. The risk-free interest rate is based on the Government of Canada benchmark bond yield rates in effect at the time of grant and the expected life of the options represents the estimated length of time the options are expected to remain outstanding.

Incentive Share Award Plan

Restricted Share Units

We have issued restricted share units ("RSUs") to non-employee directors through our incentive share award plan. Grants of RSUs to non-employee directors vest either on the third anniversary date from the grant date or when the director ceases to be a member of the board. We have also issued RSUs to certain officers and employees of the Company. Grants of RSUs to certain officers and employees of the Company vest over a three year period. The following RSUs are outstanding at June 30:

	2018	2017
Outstanding, beginning of the period	**190,407**	139,237
Granted during the period	**8,891**	9,212
Outstanding, end of the period	**199,298**	148,449

(1) The weighted average fair value of the RSUs granted was $6.27 in 2018 (2017 - $5.65).

Performance Share Units

We have also issued performance share units ("PSUs") to certain officers and employees of the Company. Grants of PSUs require completion of certain performance criteria and cliff vest after 3 years or vest over a three year period, depending on the grant. PSU grants to certain officers will vest immediately upon a change of control of the Company. If certain officers cease employment

with the Company, vesting occurs on a pro rata basis prior to the third anniversary of the grant but after the first anniversary. The following PSUs are outstanding at June 30:

	2018	2017
Outstanding, beginning of the period	**94,734**	88,419
Granted during the period	**—**	6,315
Forfeited during the period	**(31,578)**	—
Outstanding, end of the period	**63,156**	94,734

(1) The weighted average fair value of the PSUs granted in 2017 was $3.33.

We have reserved 1,652,143 common shares for issuance relating to our outstanding equity compensation plans. Compensation expense related to stock options, RSUs and PSUs was $157,092 and $696,210 for the three and six month periods ending June 30, 2018, respectively (2017 - $155,708 and $289,597, respectively).

Note 7: Loss Per Common Share

Loss per common share is calculated using net loss for the year and the weighted average number of common shares outstanding for the three and six month periods ended June 30, 2018 of 15,406,944 and 15,191,457, respectively (June 30, 2017 - 13,405,220 and 13,086,393, respectively). The effect of any potential exercise of our stock options and warrants outstanding during the year has been excluded from the calculation of diluted loss per common share, as it would be anti-dilutive.

Note 8: Contract Liability and Receivable

Regional licensing agreement
We entered into a regional licensing agreement (the "Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai") in November 2017. Under the terms of the Agreement, Adlai will have exclusive development and commercialization rights to REOLYSIN in China, Hong Kong, Macau, Singapore, South Korea and Taiwan. We are entitled to receive upfront license fees, development and regulatory milestone payments, royalties and sales-based milestone payments.

Warrant purchase agreement
We also entered into a warrant purchase agreement with Adlai. Under the terms of the warrant purchase agreement, we are entitled to receive two milestone payments totaling US$8 million made up of two common share purchase warrants:

- One common share purchase warrant of US$2 million whereby, upon exercise, Adlai may purchase our common shares priced at a 20% premium to the five-day weighted average closing price immediately preceding the exercise date. We have the right to call this warrant when the first patient is enrolled in the phase 3 metastatic breast cancer study or six months after execution of the Agreement, whichever is later.
- One common share purchase warrant of US$6 million whereby, upon exercise, Adlai may purchase our common shares priced at a 20% premium to the five-day weighted average closing price immediately preceding the exercise date. We have the right to call this warrant upon the enrollment of the 50th patient in the phase 3 metastatic breast cancer study.

Contract liability
Our contract liability balance, which we expect to record in revenue over the next five years, is as follows:

	June 30, 2018 $	December 31, 2017 $
Balance, beginning of the period	**6,182,580**	—
Regional licensing agreement	**547,707**	6,182,580
Revenue recognized in the period	—	—
Balance, end of the period	**6,730,287**	6,182,580
Contract liability - current	**927,400**	1,545,645
Contract liability - non-current	**5,802,887**	4,636,935
	6,730,287	6,182,580

Contract receivable
Our contract receivable due from Adlai at June 30, 2018 is nil (December 31, 2017 - $4,767,100 (US$3,800,000)). On collection of the contract receivable, an income tax expense of $547,707 was recorded with a corresponding credit to the contract liability.

Note 9: Commitments

We are committed to payments totaling $6,063,389 for activities related to our clinical trial, manufacturing and collaboration programs which are expected to occur over the next two years.

We are committed to rental payments (excluding our portion of operating costs and rental taxes) under the terms of our office leases. Annual payments under the terms of these leases are as follows:

	Amount $
Remainder of 2018	209,680
2019	449,360
2020	361,848
2021	162,286
	1,183,174

Under a clinical trial agreement entered into with the Alberta Cancer Board ("ACB"), we have agreed to repay the amount funded under the agreement together with a royalty, to a combined maximum amount of $400,000 plus an overhead repayment of $100,000, upon sales of a specified product. We agreed to repay the ACB in annual installments in an amount equal to the lesser of: (a) 5% of gross sales of a specified product; or (b) $100,000 per annum once sales of a specified product commence.

Note 10: Capital Disclosures

Our objective when managing capital is to maintain a strong statement of financial position. We achieve our objective by obtaining adequate cash resources to support planned activities which include the clinical trial program, product manufacturing, administrative costs and intellectual property expansion and protection. We include shareholders' equity and cash and cash equivalents in the definition of capital.

	June 30, 2018 $	December 31, 2017 $
Cash and cash equivalents	**18,741,347**	11,836,119
Shareholders' equity	**10,966,761**	8,283,846

We do not have any debt other than trade accounts payable and we have potential contingent obligations relating to the completion of our research and development of REOLYSIN.

In managing our capital, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the costs associated with these activities. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year's activity. Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.

Historically, funding for our plan is primarily managed through the issuance of additional common shares and common share purchase warrants that upon exercise are converted to common shares. Management regularly monitors the capital markets attempting to balance the timing of issuing additional equity with our progress through our clinical trial program, general market conditions, and the availability of capital. There are no assurances that funds will be made available to us when required.

On May 4, 2018, we renewed our short form base shelf prospectus (the "Base Shelf") that qualifies for distribution of up to $150,000,000 of common shares, subscription receipts, warrants, or units (the "Securities") in either Canada, the US or both. Under a Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents or other intermediaries and also may sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.

Renewing our Base Shelf provides us with additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time period required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in our company. Funds received as a result of using our Base Shelf would be used in line with our Board approved budget and multi-year plan. Our renewed Base Shelf will be effective until May 25, 2020.

We are not subject to externally imposed capital requirements and there have been no changes in how we define or manage our capital in 2018.

Note 11: Financial Instruments

Our financial instruments consist of cash and cash equivalents, other receivables and accounts payable. As at June 30, 2018, there are no significant differences between the carrying values of these amounts and their estimated market values.

Credit risk
Credit risk is the risk of financial loss if a counterparty to a financial instrument fails to meet its contractual obligations. We are exposed to credit risk on our cash and cash equivalents and contract receivable in the event of non-performance by counterparties, but we do not anticipate such non-performance. Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents and contract receivable.

We mitigate our exposure to credit risk by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada. For our foreign domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts and these accounts are used solely for the purpose of settling accounts payable or payroll.

Interest rate risk

Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in market interest rates. We are exposed to interest rate risk through our cash and cash equivalents and our portfolio of short-term investments. We mitigate this risk through our investment policy that only allows investment of excess cash resources in investment grade vehicles while matching maturities with our operational requirements.

Fluctuations in market rates of interest do not have a significant impact on our results of operations due to the short term to maturity of the investments held.

Currency risk

Currency risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. In the normal course of our operations, we are exposed to currency risk from the purchase of goods and services primarily in the U.S., the U.K. and the European Union. In addition, we are exposed to currency risk to the extent cash is held in foreign currencies from either the purchase of foreign currencies or when we receive foreign currency proceeds from operating and financing activities. As well, we are exposed to currency risk related to our regional licensing agreement. The impact of a $0.01 increase in the value of the U.S. dollar against the Canadian dollar would have decreased our net loss in 2018 by approximately $78,308. The impact of a $0.10 increase in the value of the British pound against the Canadian dollar would have increased our net loss in 2018 by approximately $15,848. The impact of a $0.10 increase in the value of the Euro against the Canadian dollar would have increased our net loss in 2018 by approximately $4,658.

We mitigate our foreign exchange risk by maintaining sufficient foreign currencies, through the purchase of foreign currencies or receiving foreign currencies from financing activities, to settle our foreign accounts payable.

Balances in foreign currencies at June 30, 2018 are as follows:

	US dollars $	**British pounds** £	**Euro** €
Cash and cash equivalents	12,698,664	29,212	23,347
Accounts payable	(916,806)	(27,060)	—
	11,781,858	2,152	23,347

Liquidity risk

Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities. We manage liquidity risk through the management of our capital structure as outlined in Note 10. Accounts payable are all due within the current operating period.

Note 12: Additional Cash Flow Disclosures

Net Change In Non-Cash Working Capital

	Three Month Period Ending June 30, 2018 $	Three Month Period Ending June 30, 2017 $	Six Month Period Ending June 30, 2018 $	Six Month Period Ending June 30, 2017 $
Change in:				
Contract receivable	**4,899,720**	—	**4,767,100**	—
Other receivables	**(50,826)**	(25,625)	**(51,988)**	(7,703)
Prepaid expenses	**(402,199)**	(302,178)	**(313,149)**	(224,234)
Accounts payable and accrued liabilities	**(204,913)**	(37,818)	**(687,585)**	(757,716)
Contract liability	**547,707**	—	**547,707**	—
Non-cash impact of foreign exchange	**(69,172)**	148,715	**(34,315)**	135,101
Change in non-cash working capital related to operating activities	**4,720,317**	(216,906)	**4,227,770**	(854,552)

Other Cash Flow Disclosures

	Three Month Period Ending June 30, 2018 $	Three Month Period Ending June 30, 2017 $	Six Month Period Ending June 30, 2018 $	Six Month Period Ending June 30, 2017 $
Cash interest received	**20,538**	14,163	**47,428**	64,878
Cash taxes paid	**3,752**	—	**3,752**	—

Note 13: Other Expenses and Adjustments

We present our expenses based on the function of each expense and therefore include realized foreign exchange gains and losses, unrealized non-cash foreign exchange gains and losses and non-cash stock based compensation associated with research and development activity as a component of research and development expenses and amortization of property and equipment and stock based compensation associated with operating activities as a component of operating expenses.

	Three Month Period Ending June 30, 2018 $	Three Month Period Ending June 30, 2017 $	Six Month Period Ending June 30, 2018 $	Six Month Period Ending June 30, 2017 $
Included in research and development expenses:				
Realized foreign exchange loss (gain)	**2,289**	45,340	**(47,505)**	(44)
Unrealized non-cash foreign exchange gain	**(161,862)**	(119,937)	**(236,996)**	(47,156)
Non-cash share based compensation	**29,551**	58,270	**330,509**	126,103
Included in operating expenses				
Amortization of property and equipment	**21,126**	25,688	**40,984**	49,724
Non-cash share based compensation	**127,541**	97,438	**365,701**	163,494
Office minimum lease payments	**74,567**	49,069	**147,316**	98,138

Note 14: Related Party Transactions

Compensation of Key Management Personnel

Key management personnel are those persons having authority and responsibility for planning, directing and controlling our activities as a whole. We have determined that key management personnel consists of the members of the Board of Directors along with certain officers of the Company.

	Three Month Period Ending June 30, 2018 $	Three Month Period Ending June 30, 2017 $	Six Month Period Ending June 30, 2018 $	Six Month Period Ending June 30, 2017 $
Short-term employee compensation and benefits	**445,493**	528,407	**956,555**	1,110,802
Termination benefits	**—**	779,666	**—**	779,666
Share-based payments	**119,867**	113,172	**486,682**	211,663
	565,360	1,421,245	**1,443,237**	2,102,131

Assumption Agreement

In November 2017, with the signing of a regional licensing agreement with upfront license fees (see Note 8), the Company triggered a liability of US$178,125 to an officer as detailed in the Assumption Agreement (see Note 12 of our audited consolidated financial statements for the year ended December 31, 2017). As at June 30, 2018, US$142,500 was included in accounts payable and accrued liabilities.

Shareholder Information

For public company filings please go to www.sedar.com or contact us at:

Oncolytics Biotech Inc.
Suite 210, 1167 Kensington Crescent NW
Calgary, Alberta, Canada T2N 1X7
tel: 403.670.7377 fax: 403.283.0858
www.oncolyticsbiotech.com

Officers

Matt Coffey, PhD
President and Chief Executive Officer
Kirk Look, CA
Chief Financial Officer
Andrew de Guttadauro
President, Oncolytics Biotech (U.S.) Inc.

Directors

Deborah M. Brown, BSc, MBA
Managing Partner, Accelera CANADA
Matt Coffey, PhD
President and CEO, Oncolytics Biotech Inc.
Angela Holtham, MBA, FCPA, FCMA, ICD.D
Corporate Director
J. Mark Lievonen, CM, FCPA, FCA, LLD
Corporate Director
Wayne Pisano
Corporate Director
William G. Rice, PhD
Chairman, President and CEO, Aptose Biosciences, Inc.
Bernd R. Seizinger, MD, PhD
Corporate Director

Oncolytics Biotech Inc.
Suite 210, 1167 Kensington Crescent NW, Calgary, AB T2N 1X7
Phone: (403) 670.7377 Fax: (403) 283.0858
www.oncolyticsbiotech.com